TABLE 1.

Immunogenetics of nonneutralizing A32-blocking RV305 C1C2-specific MAbs^a

Study	Visit	PTID	DH	Parameters for:
				Heavy chains					Light chains
				Variable segment	Joining segment	CDR3 length (aa)	% mut (nt)	Ig isotype/subclass	Variable segment	Joining segment	CDR3 length (aa)	% mut (nt)
RV144	8	RV144_140	DH677.1	1∼8	1	16	1.04	IgG1	κ1∼27	5	9	0.857
RV305	5	RV305_094	DH677.3	1∼8	1	16	3.47	IgG1	κ1∼27	5	9	2.87
RV305	5	RV305_082	DH697	1∼46	6	24	7.99	IgG1	λ1∼44	3	11	4.87
RV305	5	RV305_094	DH677.2	1∼8	1	16	2.43	IgG1	κ1∼27	5	9	2.86
RV305	5	RV305_082	DH838	3∼23	4	12	4.17	IgG1	Λ8∼61	3	10	2.22
RV305	5	RV305_094	DH677.4	1∼8	1	16	4.51	IgG1	κ1∼27	5	9	2.57
RV305	5	RV305_082	DH695	1∼2	6	22	5.56	IgG1	κ1∼39	3	9	5.30
RV305	5	RV305_082	DH694	1∼46	6	22	10.42	IgG1	κ1∼39	5	9	8.71
RV305	5	RV305_094	DH688.1	1∼46	6	23	6.97	IgG3	κ1∼39	4	9	6.00
RV305	5	RV305_094	DH705.5	1∼46	6	23	5.77	IgG3	κ3∼20	2	10	4.49
RV305	5	RV305_094	DH705.4	1∼46	6	23	6.01	IgG1	κ1∼39	5	9	3.43
RV305	5	RV305_3119	DH886	1∼2	4	12	8.38	IgG3	κ1∼39	4	9	4.92
RV305	5	RV305_031	DH690	1∼46	6	24	6.92	IgG1	λ1∼44	2	11	3.62
RV305	5	RV305_094	DH692	1∼46	6	25	1.66	IgG1	κ1∼39	4	9	2.57
RV305	5	RV305_094	DH693	1∼46	4	26	5.18	IgG1	κ1∼9	5	9	2.86
RV305	5	RV305_094	DH836	1∼46	6	16	5.32	IgG1	κ1∼12	4	9	2.86
RV305	5	RV305_094	DH688.2	1∼46	6	23	7.69	IgG3	κ1∼39	4	9	6.57
RV305	5	RV305_031	DH689.1	1∼46	6	22	10.17	IgG3	κ1∼39	2	9	9.71
RV305	5	RV305_031	DH689.2	1∼46	6	22	10.41	IgG3	κ1∼39	1	8	8.55
RV305	5	RV305_031	DH687.2	1∼46	4	23	5.77	IgG1	κ3∼20	3	10	1.97

^aPBMCs used for MAb isolation were collected 2 weeks after the final boost in RV144 or 2 weeks after the second boost in RV305. All four RV305 vaccinees studied were from group II, boosted 2× with AIDSVAX B/E. RT-PCR-amplified variable heavy- and light-chain genes were Sanger sequenced (Genewiz) and analyzed with Cloanalyst (13). PTID, patient identifier; DH, antibody identifier.